Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
SHARE THIS ARTICLE
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients with implanted cardiac devices including left ventricular assist devices (LVAD) or for those with rare cardiovascular conditions.
“This year has marked significant opportunities and advancements for Cadrenal Therapeutics, with a strong focus on clinical indications,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “The Company has established a targeted plan to advance the clinical development of tecarfarin and, if approved, to commercialize it as a significant improvement for LVAD patients facing challenges with chronic anticoagulation treatments. We look ahead to 2025 and the initiation of the pivotal Phase 3 clinical trial for tecarfarin in LVAD and developing this much-needed therapeutic solution for advanced heart failure patients with implanted LVADs.”
2024 Year-End Highlights:
- FDA Engagement and Tecarfarin Development: Cadrenal Therapeutics held a Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the pivotal Phase 3 clinical trial protocol for tecarfarin in LVAD patients. The Company remains in discussion with the FDA to further refine the trial and expects to provide updates on the anticipated trial in Q1 2025.
- Strategic Development Collaborations: Cadrenal Therapeutics continues to explore collaboration with potential development partners to advance tecarfarin’s pivotal clinical trial for patients with LVAD and other rare cardiovascular conditions.
- Financial Growth and Fundraising Success: Cadrenal Therapeutics raised approximately $9.8 million in recent financing transactions, including $5.1 million through an at-the-market (ATM) facility and $4.7 million from warrant exercises, boosting its cash balance to $11.3 million as of November 2024.
- Industry Recognition and Engagement: In October 2024, Cadrenal Therapeutics joined the Corporate Council of the Anticoagulation Forum (AC Forum). This association will enable the Company to collaborate with anticoagulation therapy thought leaders and 15,000 healthcare professionals to improve anticoagulation outcomes for patients globally. In November 2024, Cadrenal Therapeutics was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook, an industry publication focused on breakthrough pharmaceutical technologies.
- Operational Milestones: The Company and its pharmaceutical Contract Development and Manufacturing Organization (CDMO) completed necessary operational readiness activities to supply clinical trial materials for the upcoming tecarfarin pivotal Phase 3 trial in compliance with current Good Manufacturing Practices (cGMP). Cadrenal Therapeutics has also conducted market research in multiple indications, including LVAD, research that reinforces Cadrenal Therapeutics’ commitment to continuing pre-commercial work for tecarfarin.
- Orphan Drug Designation for Tecarfarin: In April 2024, Cadrenal Therapeutics received FDA Orphan Drug Designation (ODD) for tecarfarin to prevent thromboembolism in patients with LVADs and other mechanical circulatory support devices, underscoring the investigational drug’s potential impact on rare cardiovascular conditions. Tecarfarin also has ODD and Fast Track designation from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).
- Leadership: Cadrenal appointed Jeff Cole as Chief Operating Officer to oversee manufacturing, supply chain operations, intellectual property, and commercialization strategies.
- Scientific Advocacy and Clinical Evidence: The clinical need for tecarfarin was highlighted at the November 2024 European Association for Cardio-Thoracic Surgery (EACTS) Mechanical Circulatory Support Summit in an address by Mandeep R. Mehra, MD, The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and Professor, Harvard Medical School. Dr. Mehra presented compelling data on the limitations of warfarin for LVAD patients and the potential of tecarfarin, if approved, to provide a safer alternative to these patients.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biopharmaceutical company in advanced clinical development focused on developing tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.
Tecarfarin is a vitamin K antagonist (VKA) potentially representing the first new therapeutic innovation in 70 years in VKA anticoagulation. Tecarfarin is designed to be a superior and safer chronic oral anticoagulant therapy compared to warfarin for patients with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal Therapeutics’ drug candidate, tecarfarin, is expected to enter its pivotal Phase 3 trial during 2025. The Company’s clinical program for tecarfarin is supported by extensive data demonstrating the molecule’s potential as an alternative to warfarin, with safety data indicating fewer adverse events such as strokes, heart attacks, bleeds, and deaths in comparison with warfarin. The FDA granted tecarfarin orphan drug designation (ODD) for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both ODD and Fast Track designation for end-stage kidney disease (ESKD) patients with atrial fibrillation (AFib)..
For more information, please visit www.cadrenal.com and connect with the company on LinkedIn.
Safe Harbor
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding initiation of the pivotal Phase 3 clinical trial for tecarfarin in LVAD in 2025; providing updates on the anticipated trial in Q1 2025; continuing exploration of collaborations with potential development partners to advance tecarfarin’s pivotal clinical trial for patients with LVAD and other rare cardiovascular conditions; joining the Corporate Council of the Anticoagulation Forum enabling the Company to collaborate with anticoagulation therapy thought leaders and 15,000 healthcare professionals to improve anticoagulation outcomes for patients globally; and the potential of tecarfarin, if approved, to provide a safer alternative to LVAD patients. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to initiate the pivotal Phase 3 clinical trial for tecarfarin in LVAD patients in 2025 and provide trial updates as planned; the ability to enter into collaborations with development partners; the ability of tecarfarin to provide a safer alternative to LVAD patients and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Corporate and Investor Relations
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
Disclaimer
Effective Date: [August, 2024]
This website/newsletter is owned, operated, and edited by Relqo Media LLC. Any wording found in this email or disclaimer referencing "I," "we," "our," or "Relqo Media" refers to Relqo Media LLC. This webpage/newsletter is a paid advertisement, not a recommendation or an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website, you agree to the terms of our disclaimer, which are subject to change at any time.
We are not registered or licensed in any jurisdiction to provide investing advice or any advisory or consultancy services, and are therefore unqualified to give investment recommendations. Always conduct your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve as a starting point to conduct your own research and consult with a licensed professional regarding the companies profiled and discussed.
Conduct your own research. Companies with a low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences issues with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data.
This publication, its owners, and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, potentially impacting share prices. If we own any shares, we will list the relevant stock information and the number of shares here. Relqo Media LLC's business model is to receive financial compensation to promote public companies.
Purpose
These websites, social media accounts, and all associated content are provided for informational and entertainment purposes only. Relqo Media LLC engages in marketing, advertising, and brand awareness for small-cap public companies. The content, including articles, emails, tweets, and other communications across our platforms, is classified as paid advertisements and should not be considered an offer, recommendation, or solicitation to buy or sell securities. Readers and users should not rely on the information provided as a basis for making investment decisions.
Compensation Disclosure
Relqo Media LLC is compensated for its promotional services by Penzance LLC, and this compensation may include cash payments, stock options, or other financial consideration from the companies we feature. The compensation received directly impacts the content presented on our platforms and creates a significant conflict of interest.
Cadrenal Therapeutics: Relqo Media LLC has been compensated $30,000 per week since August 8, 2024, to run a marketing campaign for Cadrenal Therapeutics. This payment will continue until May 1st, 2025, bringing the total compensation to seven hundred eighty thousand dollars.
NeoVolta Inc: Relqo Media LLC has been compensated four hundred thousand dollars starting November 11, 2024, to run a marketing campaign for NeoVolta Inc. This payment will continue until March 31, 2025. Compensation represents a major conflict of interest in our ability to remain unbiased. Therefore, this communication should be viewed as a commercial advertisement only.
We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates may wish to liquidate shares of the profiled company at or near the time you receive this communication, which could negatively impact share prices. Any non-compensated alerts are purely for the purpose of expanding our database for future financially compensated investor relations efforts. Frequently, companies profiled in our alerts may experience a significant increase in volume and share price during investor relations marketing, which may decline as soon as the marketing ceases.
Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed.
The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way to ensure its accuracy. Furthermore, Relqo Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. While independent writers' works are reviewed and edited before publication, errors or omissions may occur. You should assume all information in our communications is incorrect until you verify it yourself and are encouraged never to invest based solely on the information contained in our communications.
The information in this disclaimer is subject to change at any time without notice.
Stockverse Legal Disclaimer
Earnings & Performance Disclaimer
Stockverse provides stock market data, research tools, AI-generated insights, and other financial information strictly for educational and informational purposes.
No Guarantee of Future Performance
The past performance of any stock, security, or investment strategy does not guarantee future results. Stock markets are inherently volatile, and returns are unpredictable.
Investment Risks
Investing in stocks, securities, and financial markets carries substantial risk, including the risk of total loss of capital. Users should perform independent due diligence before making investment decisions.
No Financial Advice
Stockverse does not provide financial, investment, tax, or legal advice. Any information, data, or AI-generated insights should not be considered personalized financial advice. Users should consult a licensed financial professional before making any trading or investment decisions.
AI & Data Disclaimer
Stockverse integrates artificial intelligence (AI) technology (Stockverse GPT) and third-party financial data providers to generate stock insights and market analysis.
AI Limitations & Potential Errors
Stockverse GPT is powered by OpenAI and third-party data sources. While it provides AI-driven stock analysis, it can generate inaccurate, outdated, or misleading information. AI predictions and insights are not a substitute for professional financial analysis.
Delayed & Inaccurate Data
Stock market data displayed on Stockverse may be delayed, incomplete, or inaccurate due to exchange rules, provider limitations, or data outages. Stockverse does not guarantee the accuracy, reliability, or completeness of any financial data provided.
User Responsibility
Users acknowledge that Stockverse GPT and AI-generated insights should not be relied upon for making investment decisions. All trading and financial actions are taken at the user's sole discretion and risk.
Limitation of Liability
By using Stockverse, you acknowledge and agree that:
No Liability for Financial Losses
Stockverse, its owners, affiliates, partners, and employees shall not be liable for any direct, indirect, incidental, consequential, or financial losses incurred due to reliance on data, AI-generated insights, stock recommendations, or market trends displayed on this platform.
No Warranties
Stockverse makes no warranties or representations, express or implied, regarding the accuracy, reliability, or completeness of any content provided. All information is provided "as is" and "as available."
Third-Party Data & External Links
Stockverse may link to third-party content, stock exchanges, brokers, or news sources. We do not endorse, control, or assume responsibility for the accuracy or reliability of external websites or third-party data feeds.
Use at Your Own Risk
By using Stockverse, you acknowledge that all investment decisions are made solely at your own risk, and you release Stockverse from any and all liability associated with financial losses.
Governing Law & Dispute Resolution
Jurisdiction & Applicable Law
This Agreement and any disputes arising out of or relating to Stockverse shall be governed by and construed under the laws of the State of Wyoming, without regard to conflict of law principles.
Binding Arbitration
Any disputes, claims, or controversies arising out of or related to the use of Stockverse shall be exclusively resolved through binding arbitration in Wyoming, in accordance with the rules of the American Arbitration Association (AAA).
Waiver of Class Action & Jury Trial
By using Stockverse, you agree to waive any right to participate in a class action lawsuit or jury trial against Stockverse, its owners, affiliates, and representatives.
Intellectual Property Rights
Ownership of Content
All content, design elements, trademarks, stock analysis, AI-generated insights, and proprietary data displayed on Stockverse are owned by Stockverse Holdings LLC and protected under U.S. and international copyright and intellectual property laws.
Restrictions on Use
Users may not copy, modify, distribute, sell, or republish any Stockverse content, AI-generated insights, or proprietary tools without explicit written permission from Stockverse Holdings LLC.
AI-Generated Content & Licensing
AI-generated insights, trade signals, and stock analysis provided by Stockverse GPT are proprietary and cannot be resold, republished, or distributed for commercial use without express authorization.
DMCA & Copyright Violations
Any unauthorized reproduction or use of Stockverse content may result in legal action under the Digital Millennium Copyright Act (DMCA) or applicable intellectual property laws.
Acceptance of Terms
By accessing and using Stockverse, you acknowledge that you have read, understood, and agreed to this disclaimer. If you do not agree with any part of this disclaimer, you must discontinue use of this platform immediately.
For any legal inquiries or compliance concerns, please contact:
📧 support@stockverse.com🌐 Stockverse.com